aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
MWN-AI** Summary
aTyr Pharma, Inc. (Nasdaq: ATYR) recently announced its fourth quarter and full year results for 2025, highlighting significant developments and financial updates. The company achieved a notable milestone with its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, a condition with limited treatment options. Despite not meeting its primary endpoint of reducing corticosteroid use at week 48, the study revealed clinical benefits such as improved scores on the King’s Sarcoidosis Questionnaire and demonstrated maintained lung function.
Looking ahead, aTyr is scheduled to meet with the U.S. Food and Drug Administration (FDA) in mid-April 2026 to discuss the study results and the future trajectory for efzofitimod. The company is also advancing a Phase 2 EFZO-CONNECT™ trial, expected to finalize patient enrollment in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026.
As of December 31, 2025, aTyr reported cash and investments totaling approximately $80.9 million. Research and development expenses increased to $60.2 million, primarily driven by the costs associated with ongoing clinical trials. General and administrative expenses rose to $17.6 million.
Additionally, aTyr showcased its investigational drug ATYR0101, which has demonstrated promising results in managing fibrosis via subcutaneous delivery. A recent publication in the *Journal of Biological Chemistry* outlined the creation of a bispecific antibody targeting NRP2 and PLXNA1, indicating potential anticancer applications.
Overall, aTyr Pharma appears poised for future growth as it navigates regulatory discussions and continues its pivotal research in rare lung diseases, emphasizing its commitment to innovative therapeutic solutions.
MWN-AI** Analysis
aTyr Pharma's recent disclosures provide a complex but promising outlook for investors, especially in the wake of their Phase 3 EFZO-FIT™ study. While the study did not meet its primary endpoint, several significant secondary outcomes suggest potential clinical benefits for efzofitimod in treating pulmonary sarcoidosis. The upcoming meeting with the FDA in April 2026 will be pivotal in determining the future regulatory path for the drug. Investors should carefully monitor this event, as FDA feedback could significantly influence stock performance.
With a cash position of $80.9 million at the end of 2025, aTyr appears well-resourced to advance its pipeline. However, the company must balance its development budget, given the $60.2 million spent on R&D last year. The projected completion of enrollment in the Phase 2 EFZO-CONNECT™ study in 2026 is another potential catalyst, especially if positive interim data continues to unfold.
Entering 2026, aTyr is navigating transitional waters. The stock has historically exhibited volatility due to broader market trends affecting biotech and the inherent risks associated with clinical trials. As such, consideration of market sentiment, especially post-FDA meeting, should shape investment strategies. Investors weighing entry points should assess risk tolerance and the likelihood of efzofitimod's eventual commercialization against ongoing clinical development timelines.
In summary, while aTyr Pharma faces challenges, its promising drug pipeline and robust cash reserves provide a solid foundation for future growth. Investors should maintain a watchful eye on FDA communications and further clinical results in the coming months before making strategic moves in their portfolios.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis.
Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.
Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2025 results and provided a corporate update.
“In 2025 we announced results from our Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD) where a significant proportion of patients develop chronic or progressive disease with debilitating symptoms despite current treatment options. This marked an important milestone, not only for the broader sarcoidosis community, but also for aTyr, as it was the Company’s largest and first Phase 3 study of a tRNA synthetase-derived therapy generated from our platform,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.
“We are ready and look forward to engaging with the U.S. Food and Drug Administration (FDA) in mid-April to review the results of the study and determine the path forward for efzofitimod in pulmonary sarcoidosis. We plan to provide an update regarding the next steps for the program following the receipt of the official FDA meeting minutes.”
Fourth Quarter 2025 and Subsequent Period Highlights
- Announced the scheduling of a Type C meeting with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. The Company expects to provide an update regarding the outcome of the meeting following the receipt of the official meeting minutes. EFZO-FIT™ was a Phase 3 study to evaluate the efficacy and safety of 3.0 mg/kg and 5.0 mg/kg of efzofitimod or placebo in 268 patients with symptomatic pulmonary sarcoidosis. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Clinical benefit for 5.0 mg/kg efzofitimod was observed across multiple pre-specified study efficacy parameters at week 48 compared to placebo, including the King’s Sarcoidosis Questionnaire (KSQ)-Lung score (p=0.0479), Fatigue Assessment Scale score (p=0.0226), KSQ-General Health score (p=0.0197), and complete steroid withdrawal with KSQ-Lung score improvement (p=0.0196). Additionally, treatment with efzofitimod maintained lung function as measured by forced vital capacity and was well-tolerated with a safety profile consistent with prior trials conducted to date.
- On track to complete enrollment in the Phase 2 EFZO-CONNECT™ study to evaluate the efficacy, safety and tolerability of efzofitimod in patients with limited or diffuse systemic sclerosis (SSc, or scleroderma)-related ILD (SSc-ILD) in the first half of 2026. This proof-of-concept study is a randomized, double-blind, placebo-controlled, 28-week study consisting of three parallel cohorts randomized 2:2:1 to either 270 mg or 450 mg of efzofitimod or placebo administered intravenously monthly for a total of six doses. The study intends to enroll up to 25 patients at multiple centers in the United States. Promising interim data from the study were reported in the second quarter of 2025.
- Presented a poster related to its investigational new drug candidate, ATYR0101, at the Keystone Symposia on Fibrosis: Cross Organ Pathology and Pathways to Clinical Development. The poster demonstrated that subcutaneous delivery of ATYR0101 yielded a comparable pharmacokinetic and immunogenicity profile, which is favorable to other delivery methods, while reducing lung inflammation. The findings presented in the poster suggest the ability of ATYR0101 to potentially resolve the cycle of chronic inflammation and fibrosis utilizing a novel mechanism and further support a compelling therapeutic profile for patients suffering from fibrosis. The poster is available on the Company’s website.
- Published an article demonstrating the generation of a functional neuropilin-2 (NRP2)/plexinA1 (PLXNA1) bispecific antibody in the Journal of Biological Chemistry. The publication, entitled, “A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F,” demonstrates that the bispecific antibody selectively mimics the beneficial aspects of semaphorin 3F (SEMA3F)/NRP2 signaling while avoiding potentially cross-toxic reactivity, serving as a basis for a novel anticancer therapy. The publication is available on the Company’s website and at: https://www.jbc.org/article/S0021-9258%2825%2902908-4/fulltext.
Year Ended 2025 Financial Highlights and Cash Position
- Cash & Investment Position: Cash, cash equivalents, restricted cash and available-for-sale investments as of December 31, 2025, were $80.9 million.
- R&D Expenses: Research and development expenses were $60.2 million for the year ended 2025, which consisted primarily of costs for the Phase 3 EFZO-FIT™ and Phase 2 EFZO-CONNECT™ studies and research and development costs for the Company’s preclinical product candidates.
- G&A Expenses: General and administrative expenses were $17.6 million for the year ended 2025.
About Efzofitimod
Efzofitimod is a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. In addition to the global Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis, a major form of ILD, efzofitimod is also being investigated in the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD. These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “aims,” “anticipates,” “believes,” “can,” “designed,” “expects,” “hopes,” “intends,” “look toward,” “may,” “plans,” “potential,” “project,” “suggest,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding the potential therapeutic benefits and applications of efzofitimod and ATYR0101; the potential for efzofitimod to improve patient quality of life across multiple disease related health outcomes in pulmonary sarcoidosis; the expected size of, and number of patients to be enrolled in the Phase 2 EFZO-CONNECT™ study; timelines and plans with respect to certain development activities and development goals, including the occurrence and timing of our meeting with the FDA to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis as well as our expectations with respect to the outcome of that meeting, the timing of our update for that meeting and next steps for the development of efzofitimod in pulmonary sarcoidosis; and our expectation that our Phase 2 EFZO-CONNECT™ study of efzofitimod in patients with SSc-ILD will complete enrollment in the first half of 2026. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty related to interactions with the FDA in general, risks related to our reliance on third-party partners and the potential that such partners may not perform as anticipated, the fact that NRP2 and tRNA synthetase biology is not fully understood, uncertainty regarding the ultimate long-term impact of evolving macroeconomic and geopolitical conditions, the risks inherent in using the results from the EFZO-FIT™ study to pursue FDA approval for efzofitimod in pulmonary sarcoidosis, the risk of delays in our clinical trials, risks associated with the discovery, development and regulation of our existing or future product candidates, including the uncertainty of related costs and regulatory filings and the risk that results from clinical trials or other studies may not support further development, the risk that we may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the fact that our collaboration agreements are subject to early termination, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
| ATYR PHARMA INC. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Years Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues: | ||||||||||||||||
| License and collaboration agreement revenues | $ | — | $ | — | $ | 190 | $ | 235 | ||||||||
| Total revenues | — | — | 190 | 235 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 10,891 | 12,228 | 60,219 | 54,372 | ||||||||||||
| General and administrative | 3,905 | 3,592 | 17,598 | 13,777 | ||||||||||||
| Total operating expenses | 14,796 | 15,820 | 77,817 | 68,149 | ||||||||||||
| Loss from operations | (14,796 | ) | (15,820 | ) | (77,627 | ) | (67,914 | ) | ||||||||
| Total other income (expense), net | 832 | 852 | 3,504 | 3,892 | ||||||||||||
| Consolidated net loss | (13,964 | ) | (14,968 | ) | (74,123 | ) | (64,022 | ) | ||||||||
| Net loss (gain) attributable to noncontrolling interest in Pangu BioPharma Limited | 1 | 1 | 5 | (1 | ) | |||||||||||
| Net loss attributable to aTyr Pharma, Inc. | $ | (13,963 | ) | $ | (14,967 | ) | $ | (74,118 | ) | $ | (64,023 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.14 | ) | $ | (0.18 | ) | $ | (0.80 | ) | $ | (0.86 | ) | ||||
| Shares used in computing net loss per share, basic and diluted | 98,010,084 | 82,724,659 | 92,985,359 | 74,261,265 |
| ATYR PHARMA INC. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (in thousands) | ||||||||
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Cash, cash equivalents, restricted cash and available-for-sale investments | $ | 80,922 | $ | 75,076 | ||||
| Other receivables | 873 | 1,736 | ||||||
| Property and equipment, net | 4,263 | 4,850 | ||||||
| Operating lease, right-of-use assets | 5,524 | 5,817 | ||||||
| Financing lease, right-of-use assets | 596 | 1,192 | ||||||
| Prepaid expenses and other assets | 825 | 8,159 | ||||||
| Total assets | $ | 93,003 | $ | 96,830 | ||||
| Accounts payable and accrued expenses | $ | 13,682 | $ | 13,715 | ||||
| Current portion of operating lease liability | 836 | 711 | ||||||
| Current portion of financing lease liability | 630 | 541 | ||||||
| Long-term operating lease liability, net of current portion | 10,308 | 11,144 | ||||||
| Long-term financing lease liability, net of current portion | 259 | 887 | ||||||
| Total stockholders’ equity | 67,288 | 69,832 | ||||||
| Total liabilities and stockholders’ equity | $ | 93,003 | $ | 96,830 |
| Contact: |
| Ashlee Dunston |
| Sr. Director, Investor Relations and Public Affairs |
| adunston@atyrpharma.com |
FAQ**
How does aTyr Pharma Inc. ATYR plan to address the primary endpoint shortcomings observed in the Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis during the upcoming FDA meeting in April 2026?
What additional data or evidence does aTyr Pharma Inc. ATYR believe will strengthen their position with the FDA regarding efzofitimod's efficacy and safety in pulmonary sarcoidosis after the EFZO-FIT™ study results?
Given that the Phase 2 EFZO-CONNECT™ study is on track for completion in the first half of 2026, how is aTyr Pharma Inc. ATYR preparing the market for potential insights from this trial in parallel to the FDA's evaluation of efzofitimod?
Considering aTyr Pharma Inc. ATYR ended 2025 with $80.9 million in cash, how does the company plan to allocate resources towards ongoing studies and regulatory interactions as they await the FDA's direction on efzofitimod for pulmonary sarcoidosis?
**MWN-AI FAQ is based on asking OpenAI questions about aTyr Pharma Inc. (NASDAQ: ATYR).
NASDAQ: ATYR
ATYR Trading
2.31% G/L:
$0.8472 Last:
726,211 Volume:
$0.82 Open:
